Key result
DOACs show similar six-month VTE recurrence rates in patients weighing over versus under 120 kg.
Why the study?
DOACs are currently not recommended as first-line agents in obese patients, prompting an assessment of VTE recurrence rates in this population.
Does DOAC therapy prevent VTE recurrence equally in patients weighing >120 kg compared to those weighing <120 kg?
Cohort (n=18,147)
Yes
Does DOAC therapy prevent VTE recurrence equally in patients weighing >120 kg compared to those weighing <120 kg?
Absolute Event Rate: 36% vs 34%
p-value: p=0.08
DOACs demonstrate similar 6-month VTE recurrence rates in patients weighing >120 kg compared to those <120 kg, challenging current recommendations against their use in severe obesity.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for DOAC use in severe obesity; prospective trials needed before clinical adoption.
Younis et al. (2020) conducted a cohort in Venous thromboembolism (DVT or PE) (n=18,147). Body weight >120 kg vs. Body weight <120 kg was evaluated on Six-month readmission rates for VTE recurrence (p=0.08). In patients with venous thromboembolism treated with direct oral anticoagulants, six-month VTE recurrence rates were similar between those weighing >120 kg (36%) and those weighing <120 kg (34%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: